Panax quinquefolius ginsenosides for neuroprotection in Parkinson's disease via TNF-α inhibition.

Mengshuang Zhu, Jiyang Tang, Wen Zhan, Peihai Li, Shanshan Zhang, Hairong Hou, Xiaobin Li, Meng Jin, Xuanming Zhang

Abstract read

In one paragraph

Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mengshuang ZhuEngineering Research Center of Zebrafish Models for Human Diseases and Drug Screening, Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250103, China.

Jiyang TangEngineering Research Center of Zebrafish Models for Human Diseases and Drug Screening, Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250103, China.

Wen ZhanEngineering Research Center of Zebrafish Models for Human Diseases and Drug Screening, Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250103, China.

Peihai LiEngineering Research Center of Zebrafish Models for Human Diseases and Drug Screening, Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250103, China.

Shanshan ZhangEngineering Research Center of Zebrafish Models for Human Diseases and Drug Screening, Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250103, China.

Hairong HouEngineering Research Center of Zebrafish Models for Human Diseases and Drug Screening, Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250103, China.

Xiaobin LiEngineering Research Center of Zebrafish Models for Human Diseases and Drug Screening, Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250103, China.

Meng JinEngineering Research Center of Zebrafish Models for Human Diseases and Drug Screening, Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250103, China.

Xuanming ZhangEngineering Research Center of Zebrafish Models for Human Diseases and Drug Screening, Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250103, China. zhangmx@sdas.org.

Funding

the Key Innovation Project of Qilu University of Technology (Shandong Academy of Sciences) 2025ZDZX14the Key R&D Program of Shandong Province 2025TSGCXTHG043the Taishan Scholar Project from Shandong Province tsqn202312233the Two Hundred Foreign Experts Program WSP2024016the Two Hundred Foreign Experts Program WSR2024032

6 · The paper itself

Abstract

Parkinson's disease (PD) is characterized by resting tremors and gradual loss of dopaminergic (DA) neurons, increasing the socio-economic burden worldwide. This study aimed to investigate the neuroprotective effects of Panax quinquefolius using the MPTP-induced zebrafish PD model. The length and fluorescence intensity of DA neurons were restored to 96.55% and 73.47% of the control values, respectively, under 25 μg/mL total ginsenoside (TG) treatment. The number of blood vessels in the brain was restored to 91.48% of the control values. The swimming distance and speed of zebrafish were restored to 88.21% and 88.19% of the control values, respectively. A total of 15 ginsenosides were identified from TG using liquid chromatography quadrupole time-of-flight mass spectrometry for exploring their actions on PD. The in silico analyses revealed ginsenoside Rg5, pseudoginsenoside F11, and ginsenoside F4 as the key active components, and tumor necrosis factor (TNF), albumin (ALB), TP53, and interleukin (IL)-6 as the important targets with higher correlation degrees. Molecular docking toward TNF-α demonstrated excellent binding affinities with energy values of -7.18 kcal/mol (ginsenoside Rg5), -6.85 kcal/mol (pseudoginsenoside F11), and -7.34 kcal/mol (ginsenoside F4). Quantitative polymerase chain reaction and enzyme-linked immunosorbent assay showed that ginsenosides inhibited MPTP-induced upregulation of TP53 and IL-6 and reversed the downregulation of VDBP, a homologous transport protein of ALB in the zebrafish model. It was speculated that ginsenosides might influence TNF-α protein, which in turn could modulate the downstream TP53, IL-6, and VDBP (ALB) expression, representing an effective mechanism for alleviating PD symptoms.

Indexed as

GinsenosidesNeuroprotective AgentsPanaxParkinson DiseaseTumor Necrosis Factor-alphaAnimalsDisease Models, AnimalDopaminergic NeuronsInterleukin-6MaleMolecular Docking SimulationZebrafishGinsenosidesInterleukin-6Neuroprotective AgentsTumor Necrosis Factor-alphaAction mechanismGinsenosidesNeuroprotective effectPanax quinquefoliusParkinson’s disease

Identifiers

PMID42573907

DOI10.30773/pi.2020.0185

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.